3,3′-diindolylmethane ameliorates non-alcoholic fatty liver disease by inhibiting the FMO3-TMAO axis in mice
Biochemical and Biophysical Research Communications · 2026
DOI: 10.1016/j.bbrc.2026.153641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026. Verfasst von Runsheng Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biliary-Pancreatic Center, The Affiliated Hospital of Southwest Medical University, Luzhou, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Oxygenases, Methylamines, Indoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Sichuan Medical Association, Chinese Medical Association, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
Non-alcoholic fatty liver disease (NAFLD) is the leading chronic liver disease globally, characterized by steatosis, inflammation, and hepatocyte injury. While the Flavin-containing monooxygenase 3 (FMO3)-trimethylamine N-oxide (TMAO) axis is a known driver of atherosclerosis, its role in NAFLD progression remains unclear. Here, we report that FMO3 is significantly upregulated in the livers of choline-deficient, high-fat diet (CDA-HFD)-induced NAFLD mice, as revealed by transcriptomic profiling and validation. Mechanistically, FMO3 overexpression exacerbated lipid accumulation and inflammatory cytokine release in vitro, while its metabolite TMAO directly aggravated hepatic steatosis and inflammation in vivo. Notably, the natural compound 3,3'-diindolylmethane (DIM) significantly attenuated NAFLD phenotypes, including serum ALT/AST levels and hepatic lipid content; however, these protective effects were reversed by exogenous TMAO supplementation. These findings identify the FMO3-TMAO axis as a critical target for regulating lipid homeostasis and inflammation, suggesting DIM as a promising therapeutic candidate for NAFLD intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biliary-Pancreatic Center, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
- Department of Biliary-Pancreatic Center, The Affiliated Hospital of Southwest Medical University, Luzhou, China; Metabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, Academician (Expert) Workst…
Förderung
- Sichuan Medical Association
- Chinese Medical Association
- Natural Science Foundation of Sichuan Province
- Sichuan Provincial Postdoctoral Science Foundation
- China Postdoctoral Science Foundation
- Sichuan Provincial Youth Science and Technology Fund
- Southwest Medical University
- National Natural Science Foundation of China
Zitieren
APA
Chen, R., Liu, H., Yang, T., Jiang, Z., He, Z., Zhang, X., Qian, B., & Fu, W. (2026). 3,3′-diindolylmethane ameliorates non-alcoholic fatty liver disease by inhibiting the FMO3-TMAO axis in mice. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2026.153641
Vancouver
Chen R, Liu H, Yang T, Jiang Z, He Z, Zhang X, et al. 3,3′-diindolylmethane ameliorates non-alcoholic fatty liver disease by inhibiting the FMO3-TMAO axis in mice. Biochemical and Biophysical Research Communications. 2026. doi:10.1016/j.bbrc.2026.153641
BibTeX
@article{Chen2026,
author = {Chen, Runsheng and Liu, Hua and Yang, Tinfeng and Jiang, Zhonghao and He, Zeyu and Zhang, Xinpeng and Qian, Baolin and Fu, Wenguang},
title = {3,3′-diindolylmethane ameliorates non-alcoholic fatty liver disease by inhibiting the FMO3-TMAO axis in mice},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
doi = {10.1016/j.bbrc.2026.153641}
}
EUVIMED